You are here: Industry Insights > Medicago

News List

Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate AmericanPharmaceuticalReview
December 09, 2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago's plant-based COVID-19 vaccine candidate in...
Positive mid-stage results for Medicago and GSK’s plant-derived COVID-19 vaccine pharmatimes
May 18, 2021
Medicago and GlaxoSmithKline’s (GSK) plant-derived COVID-19 vaccine has generated some promising mid-stage trial results, the companies revealed today.
Health Canada to review rolling submission for Medicago’s Covid-19 vaccine pharmaceutical-technology
April 27, 2021
Health Canada has accepted for review the first portion of the rolling submission by Medicago for its plant-derived adjuvanted Covid-19 vaccine candidate.
GSK, Medicago launch late-stage trial of plant-derived COVID-19 vaccine pharmatimes
March 18, 2021
GlaxoSmithKline (GSK) and Canadian biopharma company Medicago have launched a Phase III trial of their adjuvanted plant-derived COVID-19 vaccine candidate.
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate worldpharmanews
November 16, 2020
Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity.
Medicago’s COVID-19 vaccine elicits immune response in early-stage study expresspharma
November 12, 2020
Medicago did not disclose full safety data, but said side effects were mainly mild to moderate.
PMI announces Medicago to supply up to 76 mn doses of its plant-derived COVID-19 vaccine candidate expresspharma
October 29, 2020
Medicago began the phase I testing on volunteers on July 14 and is anticipating that phase II trials will begin in early November 2020.
Plant-based COVID-19 vaccine enters Phase I trials europeanpharmaceuticalreview
July 23, 2020
The vaccine containing a recombinant coronavirus virus-like particles (CoVLP) will be tested in three different doses and with two different adjuvants.
GSK, Medicago Enter COVID-19 Vax Tie-up contractpharma
July 14, 2020
Combines plant-based and adjuvant technologies to develop and produce a COVID-19 candidate vaccine.
GSK links with Medicago to develop novel COVID-19 vaccine pharmatimes
July 09, 2020
GSK and Canadian biopharma Medicago are joining forces on the development and evaluation of a COVID-19 candidate vaccine combining the former's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system.

Previous page 1 2 Next page